Sivelestat
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 127373-66-4 |
PubChem (CID) | 107706 |
IUPHAR/BPS | 6441 |
ChemSpider | 96875 |
UNII | DWI62G0P59 |
KEGG | D03788 |
ChEMBL | CHEMBL76688 |
Chemical and physical data | |
Formula | C20H22N2O7S |
Molar mass | 434.46 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Sivelestat (INN, research name ONO 5046, marketed as Elaspol) is an inhibitor of human neutrophil elastase.[1]
It is used in the treatment of acute respiratory failure[2] and preliminary studies show it may also improve neuropathic pain.[3]
Synthesis
Sivelestat is synthesised as follows:[4]
References
- ↑ Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T (June 1991). "ONO-5046, a novel inhibitor of human neutrophil elastase". Biochem. Biophys. Res. Commun. 177 (2): 814–20. doi:10.1016/0006-291X(91)91862-7. PMID 2049103.
- ↑ Imokawa S, Mori K, Harada M, et al. (June 2008). "[Acute respiratory failure due to pneumocystis pneumonia successfully treated with combined use of sivelestat sodium hydrate]". Nihon Kokyuki Gakkai Zasshi (in Japanese). 46 (6): 461–5. PMID 18592991.
- ↑ Weyer, Andy D.; Stucky, Cheryl L. (May 2015). "Repurposing a leukocyte elastase inhibitor for neuropathic pain". Nature Medicine. 21 (5): 429–430. doi:10.1038/nm.3861. ISSN 1078-8956.
- ↑ K. Imaki, Y. Arai, T. Okegawa, U.S. Patent 5,017,610 (1991).
This article is issued from Wikipedia - version of the 7/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.